The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

Chowdhury, Rasheduzzaman, Yeoh, Kar Kheng, Tian, Ya‐Min, Hillringhaus, Lars, Bagg, Eleanor A, Rose, Nathan R, Leung, Ivanhoe K H, Li, Xuan S, Woon, Esther C Y, Yang, Ming, McDonough, Michael A, King, Oliver N, Clifton, Ian J, Klose, Robert J, Claridge, Timothy D W, Ratcliffe, Peter J, Schofield, Christopher J, Kawamura, Akane·2011·The EMBO Reports

DOI 10.1038/embor.2011.43

Cited by (1,000)

Items 601–700 of 1,000

Ultimate Precision: Targeting Cancer but Not Normal Self-replication
Vamsidhar Velcheti, David S. Schrump, Yogen Saunthararajah · 2018 · American Society of Clinical Oncology Educational Book
Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs
Satish K. Chitneni, Zachary J. Reitman, David M. Gooden, Hai Yan, Michael R. Zalutsky · 2016 · European Journal of Medicinal Chemistry
Epigenome modifiers and metabolic rewiring: New frontiers in therapeutics
Ferrari, Alessandra, Longo, Raffaella, Silva, Rui, Mitro, Nico, Caruso, Donatella, De Fabiani, Emma, Crestani, Maurizio · 2019 · Pharmacology & Therapeutics
The 2021 World Health Organization Central Nervous System Tumor Classification: The Spectrum of Diffuse Gliomas
Racine Gue, Dhairya A. Lakhani · 2024 · Biomedicines
New Approaches with Precision Medicine in Adult Brain Tumors
Annette Leibetseder, Matthias Preusser, Anna Sophie Berghoff · 2022 · Cancers
Epigenetic Regulation in Uterine Fibroids—The Role of Ten-Eleven Translocation Enzymes and Their Potential Therapeutic Application
Marta Włodarczyk, Grażyna Nowicka, Michał Ciebiera, Mohamed K. Ali, Qiwei Yang, Ayman A. Al-Hendy · 2022 · International Journal of Molecular Sciences
A D-2-hydroxyglutarate dehydrogenase mutant reveals a critical role for ketone body metabolism in Caenorhabditis elegans development
Olga Ponomarova, Hefei Zhang, Xuhang Li, Shivani Nanda, Thomas B. Leland, Bennett William Fox, Alyxandra N. Starbard, Gabrielle E. Giese, Frank C. Schroeder, Lutfu Safak Yilmaz et al. · 2023 · PLoS Biology
The two enantiomers of 2-hydroxyglutarate differentially regulate cytotoxic T cell function
Iosifina P. Foskolou, Pedro P. Cunha, Elena Sánchez‐López, Eleanor Minogue, Benoît P. Nicolet, Aurélie Guislain, Christian Jorgensen, Sarantos Kostidis, Nordin D. Zandhuis, Laura Barbieri et al. · 2023 · Cell Reports
Allosterically inhibited PFKL via prostaglandin E2 withholds glucose metabolism and ovarian cancer invasiveness
Shengmiao Chen, Yiran Wu, Yang Gao, Chenxu Wu, Yuetong Wang, Chun Hou, Miao Ren, Shuyuan Zhang, Qi Zhu, Jiali Zhang et al. · 2023 · Cell Reports
Transcriptional regulation of amino acid metabolism by KDM2B, in the context of ncPRC1.1 and in concert with MYC and ATF4
Evangelia Chavdoula, Vollter Anastas, Alessandro La Ferlita, Julian Aldana, Giuseppe Carota, Mariarita Spampinato, Burak Soysal, Ilaria Cosentini, Sameer Parashar, Anuvrat Sircar et al. · 2023 · Metabolism
Steroids from Ganoderma sinense as new natural inhibitors of cancer-associated mutant IDH1
Mengzhu Zheng, Ruotian Tang, Yue Deng, Kaiyin Yang, Lixia Chen, Hua Li · 2018 · Bioorganic Chemistry
Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells
Jiao Chen, Jie Yang, Qingyun Wei, Ling Weng, Fei Wu, Yun Yu Shi, Xiaolan Cheng, Xueting Cai, Chunping Hu, Peng Cao · 2020 · Cell Communication and Signaling
Engineering Biological C–H Functionalization Leads to Allele-Specific Regulation of Histone Demethylases
Megan Breski, Debasis Dey, Sara Obringer, Babu Sudhamalla, Kabirul Islam · 2016 · Journal of the American Chemical Society
D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant–Induced MIR148A Promoter Methylation
Tie Li, Christopher D. Cox, Byram Hirsch Ozer, Nhung T. Nguyen, HuyTram N. Nguyen, Thomas J. Lai, Sichen Li, Fei Liu, Harley I. Kornblum, Linda M. Liau et al. · 2018 · Molecular Cancer Research
Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration
Hengyi Cao, Guangya Zhu, Lin Sun, Ge Chen, Xinxin Ma, Xiao Luo, Jidong Zhu · 2019 · European Journal of Medicinal Chemistry
Fermentative Production of l-2-Hydroxyglutarate by Engineered Corynebacterium glutamicum via Pathway Extension of l-Lysine Biosynthesis
Carina Prell, Arthur Burgardt, Florian Meyer, Volker F. Wendisch · 2021 · Frontiers in Bioengineering and Biotechnology
Metabolomics of Glioma
Sizhe Feng, Yutong Liu · 2021 · Advances in experimental medicine and biology
Distinct Roles of Glutamine Metabolism in Benign and Malignant Cartilage Tumors With IDH Mutations
Hongyuan Zhang, Vijitha Puviindran, Puviindran Nadesan, Xiruo Ding, Leyao Shen, Yuning J. Tang, Hidetoshi Tsushima, Yasuhito Yahara, Ga I Ban, Guofang Zhang et al. · 2020 · Journal of Bone and Mineral Research
The Interplay between Dysregulated Metabolism and Epigenetics in Cancer
Mahmoud Adel Bassal · 2023 · Biomolecules
MTOR modulation induces selective perturbations in histone methylation which influence the anti-proliferative effects of mTOR inhibitors
HaEun Kim, Benjamin Lebeau, David J. Papadopoli, Predrag Jovanović, Mariana De Sa Tavares Russo, Daina Zofija Avizonis, Masahiro Morita, Farzaneh Afzali, Josie Ursini‐Siegel, Lynne-Marie M Postovit et al. · 2024 · iScience
Tetracyanoresorcin[4]arene selectively recognises trimethyllysine and inhibits its enzyme-catalysed demethylation
Hayden Peacock, Cyrille C. Thinnes, Akane Kawamura, Andrew D. Hamilton · 2016 · Supramolecular chemistry
Targeted Differentiation Therapy with Mutant IDH Inhibitors: Early Experiences and Parallels with Other Differentiation Agents
Eytan M. Stein, Katharine E. Yen · 2017 · Annual Review of Cancer Biology
IDH1‑R132H mutation radiosensitizes U87MG glioma cells via epigenetic downregulation of TIGAR
Narui Yin, Ting Xie, Haowen Zhang, Jian Chen, Jiahua Yu, Fenju Liu · 2019 · Oncology Letters
Interplay Between Glucose Metabolism and Chromatin Modifications in Cancer
Rui Ma, Yinsheng Wu, Shanshan Li, Xilan Yu · 2021 · Frontiers in Cell and Developmental Biology
Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma
Feng Ru Tang, Zhiyong Pan, Yi Wang, Tian Lan, Mengyue Wang, Fengping Li, Wei Quan, Zhen‐Yuan Liu, Zefen Wang, Zhiqiang Li · 2022 · Neuroscience Bulletin
Immunometabolite L-2-HG promotes epigenetic modification of exhausted T cells and improves antitumor immunity
Yanying Yang, Xiaoyan Li, Fangming Liu, Mingyue Ma, Ying Yang, Cheng‐Chao Ruan, Yan Lü, Xiaoyang Li, Xiangdong Wang, Ying–Hong Shi et al. · 2025 · JCI Insight
Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial
Katharine Jann Drummond, Montana Spiteri, Sarah A. Cain, Jordan Jones, Sammy Shaya, Monique D. Topp, Tianyao Lu, Robert Tobler, Adam Valkovic, Zachery Moore et al. · 2025 · Nature Medicine
Metabolism of glioblastoma: a review of metabolic adaptations and metabolic therapeutic interventions
James Chung, Jawad Saad, Ahmad Kafri, Julien Rossignol, Maxwell Verbrugge, Jesse Bakke · 2025 · Frontiers in Oncology
Metabolomic Phenotyping of Gliomas: What Can We Get with Simplified Protocol for Intact Tissue Analysis?
Paulina Zofia Goryńska, Kamila Chmara, Bogumiła Kupcewicz, Krzysztof Goryński, Karol Jaroch, Dariusz Pa̧czkowski, Jacek Furtak, Marek Harat, Barbara Bojko · 2022 · Cancers
Local and systemic effects of IDH mutations on primary glioma patients
Feng Ru Tang, Danwen Wang, Xi Chen, Jin‐Zhou Yang, Zhen‐Yuan Liu, Donghu Yu, Ze‐Fen Wang, Zhiqiang Li · 2023 · Immunology
Chemical approaches to study metabolic networks
Daniel A. Medina-Cleghorn, Daniel K. Nomura · 2013 · Pflügers Archiv - European Journal of Physiology
Analysis of JmjC Demethylase-Catalyzed Demethylation Using Geometrically-Constrained Lysine Analogues
Gareth W. Langley, Anne Brinkø, Martin Münzel, Louise J. Walport, Christopher John Schofield, Richard J. Hopkinson · 2015 · ACS Chemical Biology
PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas
Robert F. Koncar, Zhengtao Chu, Lindsey E. Romick‐Rosendale, Susanne I. Wells, Timothy An-thy Chan, Xiaoyang Qi, El Mustapha Bahassi · 2017 · Oncotarget
Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ 1
Hiroaki Fujiwara, Keisuke Tateishi, Hiroyuki Kato, Takuma Nakatsuka, Keisuke Yamamoto, Yasuo Tanaka, Hideaki Ijichi, Naminatsu Takahara, Suguru Mizuno, Hirofumi Kogure et al. · 2018 · Cancer Science
Tumour metabolites hinder DNA repair
Leilei Chen, Yue Xiong · 2020 · Nature
Metabolomic comparison between cells over‐expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism
He Wen, Hye Rim Cho, Taeho Yun, Hyeonjin Kim, Chul‐Kee Park, Se‐Hoon Lee, Seung Hong Choi, Sunghyouk Park · 2014 · Journal of Neurochemistry
An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors
Sara Verdura, Elisabet Cuyàs, Jesús Lozano‐Sánchez, Cristian Bastidas-Velez, Laura Llorach-Parés, Salvador Fernández‐Arroyo, Anna Hernández‐Aguilera, Jorge Joven, Alfons Nonell‐Canals, Joaquim Bosch‐Barrera et al. · 2018 · Carcinogenesis
Fitting algorithms and baseline correction influence the results of non‐invasive in vivo quantitation of 2‐hydroxyglutarate with 1H‐MRS
Katharina Johanna Wenger, Elke Hattingen, Patrick N. Harter, Christian Paolo Richter, Kea Franz, Joachim Peter Steinbach, Oliver Bähr, Ulrich Pilatus · 2018 · NMR in Biomedicine
Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone?
Giulia Trovarelli, Marta Sbaraglia, Andrea Angelini, Elena Bellan, Elisa Pala, Elisa Belluzzi, Assunta Pozzuoli, Chiara Borga, Angelo Paolo Dei Tos, Pietro Ruggieri · 2024 · Clinical Orthopaedics and Related Research
IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH ‐mutant astrocytoma PMMRDIA : a systematic review
Olfat Ahmad, Tahani M. Ahmad, Stefan Michael Pfister · 2024 · Molecular Oncology
Role of isocitrate dehydrogenase in glioma
Brian Michael Alexander, Minesh P. Mehta · 2011 · Expert Review of Neurotherapeutics
Another small molecule in the oncometabolite mix: L-2-Hydroxyglutarate in kidney cancer
Eun‐Hee Shim, Sunil Sudarshan · 2015 · Oncoscience
Abundance of d ‐2‐hydroxyglutarate in G2/M is determined by FOXM1 in mutant IDH1‐expressing cells
Balabhaskararao Kancharana, Kumar Katragunta, Uma Maheswara Sarma, Nishant Jain · 2019 · FEBS Letters
Mir142 loss unlocks IDH2R140-dependent leukemogenesis through antagonistic regulation of HOX genes
A. Marshall, J. Kasturiarachchi, P. Datta, Yan-Ping Guo, Elitza Deltcheva, C. James, Jamie Brown, G. May, Nelomi Anandagoda, I. Jackson et al. · 2020 · Scientific Reports
In vitro and in vivo analysis of metabolites involved in the TCA cycle and glutamine metabolism associated with cisplatin resistance in human lung cancer
Jiwei Guo, Jing Yu, Feng Peng, Jinzi Li, Zhi‐Rong Tan, Yao Chen, Tai Rao, Yicheng Wang, Jingbo Peng, Hong‐Hao Zhou · 2021 · Expert Review of Proteomics
Highlighting the mechanistic role of Olutasidenib (FT-2102) in the selective inhibition of mutated isocitrate dehydrogenase 1 (mIDH1) in cancer therapy
Elliasu Yakubu Salifu, Clement Agoni, Mahmoud E. S. Soliman · 2021 · Informatics in Medicine Unlocked
A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D‐2‐hydroxyglutaric aciduria type II mouse model
Fang Wang, Jeremy M. Travins, Zhi‐Zhong Lin, Yaguang Si, Yue Chen, Josh Powe, Stuart Murray, Dongwei Zhu, Erin Artin, Stefan Größ et al. · 2016 · Journal of Inherited Metabolic Disease
Metabolic orchestration of T lineage differentiation and function
Carmen S. M. Yong, Daouda Abba Moussa, Gaspard Cretenet, Sandrina Kinet, Valérie Dardalhon, Naomi N. Taylor · 2017 · FEBS Letters
Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability
Kathryn Gunn, Julie-Aurore Losman · 2024 · Cold Spring Harbor Perspectives in Medicine
Deciphering the multifaceted roles and clinical implications of 2-hydroxyglutarate in cancer
Jie Hao, Ziyi Huang, Siyue Zhang, Kefan Song, Juncheng Wang, Chao Gao, Zhiqing Fang, Ning Zhang · 2024 · Pharmacological Research
The epigenetic dysfunction underlying malignant glioma pathogenesis
Sharvari Dharmaiah, Jason T. Huse · 2022 · Laboratory Investigation
Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma
Qing-Xin Wang, Peng-Yu Zhang, Qingqing Li, Zhen‐Jiang Tong, Shao‐Peng Yu, Yan‐Cheng Yu, Yan‐Cheng Yu, Ning Ding, Xue-Jiao Leng, Liang Chang et al. · 2023 · European Journal of Medicinal Chemistry
Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation
Birgit Geoerger, Manuel Schiff, Virginie Penard‐Lacronique, Niklas Darín, Selim-Maria Saad, Clarisse Duchon, Antonin Lamazière, Aurore Desmons, Clément Pontoizeau, Pablo Berlanga et al. · 2023 · Nature Medicine
2-hydroxyglutarate rides the cancer-immunity cycle
Iosifina P. Foskolou, Lukas Bunse, Jan Van den Bossche · 2023 · Current Opinion in Biotechnology
Regulatory RNAs: role as scaffolds assembling protein complexes and their epigenetic deregulation
Palmiro Poltronieri · 2024 · Exploration of Targeted Anti-tumor Therapy
Metabolic alteration in tumorigenesis
Hui Yang, Yue Xiong, Kun‐Liang Guan · 2013 · Science China Life Sciences
A New Hydroxy Metabolite of 2-Oxoglutarate Regulates Metabolism in Hypoxia
Adrian Llewellyn Harris · 2015 · Cell Metabolism
New Insights in AML Biology From Genomic Analysis
Ashley Marie Perry, Eyal C. Attar · 2014 · Seminars in Hematology
The Enzymology of 2-Hydroxyglutarate, 2-Hydroxyglutaramate and 2-Hydroxysuccinamate and Their Relationship to Oncometabolites
Vivek Hariharan, Travis T. Denton, Sarah Paraszcszak, Kyle McEvoy, Thomas M. Jeitner, Boris F. Krasnikov, Arthur J.L. Cooper · 2017 · Biology
Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas
Ourania Romanidou, Vassiliki Kotoula, George Fountzilas · 2018 · Cancer Genomics & Proteomics
Therapeutic targeting of chromatin alterations in leukemia and solid tumors
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna M. Thomas, Michael W.M. Kühn, Michael Lübbert · 2025 · International Journal of Cancer
Hypermethylation of LATS2 Promoter and Its Prognostic Value in IDH-Mutated Low-Grade Gliomas
Yuan Gu, Yu Wang, Yebin Wang, Jiaqian Luo, Xin Wang, Mingyue Ma, Wei Hua, Ying Liu, Fa‐Xing Yu · 2020 · Frontiers in Cell and Developmental Biology
Cardio-Onco-Metabolism – Metabolic vulnerabilities in cancer and the heart
Anja Karlstaedt, Heinrich Taegtmeyer · 2022 · Journal of Molecular and Cellular Cardiology
Roles of Chromatin Remodelling and Molecular Heterogeneity in Therapy Resistance in Glioblastoma
Huey‐Miin Chen, Ana Nikolić, Divya Singhal, Marco Gallo · 2022 · Cancers
Bone regeneration strategies based on organelle homeostasis of mesenchymal stem cells
Liangjing Xin, Yao Wen, Jinlin Song, Tao Chen, Qiming Zhai · 2023 · Frontiers in Endocrinology
Structure and biochemical characterization of l-2-hydroxyglutarate dehydrogenase and its role in the pathogenesis of l-2-hydroxyglutaric aciduria
Jun Yang, Xingchen Chen, Shan Jin, Jianping Ding · 2023 · Journal of Biological Chemistry
Potential therapies targeting nuclear metabolic regulation in cancer
Yanjie Chen, Jie Xu, Xiaoyi Liu, Linlin Guo, Ping Yi, Chunming Cheng · 2023 · MedComm
Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors
Yosuke Kitagawa, Ami Kobayashi, Daniel P. Cahill, Hiroaki Wakimoto, Shota Tanaka · 2024 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Genetic, Epigenetic, and Microenvironmental Drivers of Cholangiocarcinoma
Vijay Putatunda, Apinya Jusakul, Lewis Rowland Roberts, Xin Wei Wang · 2024 · American Journal Of Pathology
2‐Hydoxyglutarate: D/Riving Pathology in gLiomaS
Daniel Richard Wahl, Sriram Venneti · 2015 · Brain Pathology
Oxidative Demethylation of DNA and RNA Mediated by Non‐Heme Iron‐Dependent Dioxygenases
Lining Lu, Chenxu Zhu, Bo Xia, Chengqi Yi · 2014 · Chemistry - An Asian Journal
Selective Inhibitors of a Human Prolyl Hydroxylase (OGFOD1) Involved in Ribosomal Decoding
Cyrille C. Thinnes, Christopher T. Lohans, Martine I. Abboud, Tzu‐Lan Yeh, Anthony Tumber, Radosław P. Nowak, Martin Attwood, Matthew E. Cockman, Udo C. T. Oppermann, Christoph Loenarz et al. · 2018 · Chemistry - A European Journal
Targeted therapy of acute myeloid leukemia
Benedito A. Carneiro, Jessica Kaplan Altman, Jason Benjamin Kaplan, Gert Jan Ossenkoppele, Ronan T. Swords, Leonidas C. Platanias, Francis Joseph Giles · 2015 · Expert Review of Anticancer Therapy
Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma
Sanne A. M. van Lith, Anna Catharina Navis, Krissie Lenting, Kiek N. Verrijp, Jan T. G. Schepens, Wiljan J A J Hendriks, Nil A. Schubert, Hanka Venselaar, Ron A. Wevers, Arno van Rooij et al. · 2016 · Scientific Reports
Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants
Diego Avellaneda Matteo, Grace A. Wells, Lucas A. Luna, Adam J. Grunseth, Olga P. Zagnitko, David A. Scott, An D. Hoang, Amit Luthra, Manal A. Swairjo, Jamie M. Schiffer et al. · 2018 · Biochemical Journal
Degradation of D-2-hydroxyglutarate in the presence of isocitrate dehydrogenase mutations
Raffaela S. Berger, Lisa Ellmann, Jörg Reinders, Marina P Kreutz, Thomas Stempfl, Peter Josef Oefner, Katja Dettmer · 2019 · Scientific Reports
Mitochondria and Epigenetic Regulation: Bidirectional Crosstalk and Emerging Mitochondria-Targeted Degron Tools
Yingwei Xu, Xiaokun Jian, Lei Shi, Lisa S. Shock, Lanming Chen, Louise T. Chow, Hengbin Wang · 2026 · Cells
Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
Giovanni Brandi, Chiara Deiana, Linda Galvani, Andrea Palloni, Angela Dalia Ricci, Alessandro Rizzo, Simona Tavolari · 2023 · Frontiers in Oncology
Olaparib in treatment‐refractory isocitrate dehydrogenase 1 ( IDH1 )– and IDH2 ‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
Michael Cecchini, Mary Jo Pilat, Nataliya Volodymyrivna Uboha, Nilofer Saba Azad, May Thet Cho, Elizabeth J. Davis, Jordi Ahnert Rodon, Gabriel Tinoco, Geoffrey Ira Shapiro, Simon Khagi et al. · 2025 · Cancer
Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications
Sang Min Lee, Arielle Rose Urman, Pinkal M. Desai · 2019 · Leukemia & lymphoma/Leukemia and lymphoma
Association of Isocitrate Dehydrogenase (IDH) Status With Edema to Tumor Ratio and Its Correlation With Immune Infiltration in Glioblastoma
Daniel Dubinski, Sae‐Yeon Won, Maximilian Rauch, Bedjan Behmanesh, Lionel Dejeumen Claude Ngassam, Peter Baumgarten, Christian Senft, Patrick N. Harter, Joshua D. Bernstock, Thomas M. Freiman et al. · 2021 · Frontiers in Immunology
Emerging Roles of Wild-type and Mutant IDH1 in Growth, Metabolism and Therapeutics of Glioma
Matthew C. Garrett, Yuki Fujii, Natsuki Osaka, Doshun Ito, Yoshihisa Hirota, Atsuo T. Sasaki · 2021 · Exon Publications eBooks
The Interplay Between Prostate Cancer Genomics, Metabolism, and the Epigenome: Perspectives and Future Prospects
Reema Singh, Ian Geoffrey Mills · 2021 · Frontiers in Oncology
Sensing cellular states—signaling to chromatin pathways targeting Polycomb and Trithorax group function
Addie M. Kolybaba, Anne-Kathrin Classen · 2014 · Cell and Tissue Research
Evidence that 2-hydroxyglutarate is not readily metabolized in colorectal carcinoma cells
Susan J. Gelman, Nathaniel G. Mahieu, Kevin Cho, Elizabeth M. Llufrio, Timothy A. Wencewicz, Gary J. Patti · 2015 · Cancer & Metabolism
Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis
Patricia D.B. Tiburcio, Bing Xiao, Shauna Berg, Sydney Asper, Sean B. Lyne, Yan Zhang, Xingen Zhu, Hai Yan, L. Eric Huang · 2017 · Acta Neuropathologica
Insights into the Action of Inhibitor Enantiomers against Histone Lysine Demethylase 5A
John R. Horton, Xu Liu, Lizhen Wu, Kai Zhang, John R. Shanks, Xing Zhang, Ganesha Rai, Bryan T. Mott, Daniel J. Jansen, Stephen C. Kales et al. · 2018 · Journal of Medicinal Chemistry
Response Kinetics and Clinical Benefits of Nonintensive AML Therapies in the Absence of Morphologic Response
Eytan M. Stein, Courtney Denton Dinardo, Daniel Aaron Pollyea, Andre C. Schuh · 2019 · Clinical Lymphoma Myeloma & Leukemia
The Distribution and Significance of IDH Mutations in Gliomas
Marta Mellai, Valentina Caldera, Laura Annovazzi, Davide Schiffer · 2013 · InTech eBooks
Yeast Systems Biology
Juan Ignacio Castrillo, Pınar Pir, Stephen G. Oliver · 2012 · Elsevier eBooks
Impairment of astrocytic glutaminolysis in glutaric aciduria type I
Shoko Komatsuzaki, Raga Deepthi Ediga, Jürgen G. Okun, Stefan Kölker, Sven W. Sauer · 2017 · Journal of Inherited Metabolic Disease
The oncometabolite L-2-hydroxyglutarate is a common product of dipteran larval development
Nader H. Mahmoudzadeh, Alexander J. Fitt, Daniel B. Schwab, William E. Martenis, Lauren M. Nease, Charity G. Owings, Garrett J. Brinkley, Hongde Li, Jonathan A. Karty, Sunil Sudarshan et al. · 2020 · Insect Biochemistry and Molecular Biology
Insights into the malfunctioning of the mitochondrial citrate carrier: Implications for cell pathology
Vincenzo Zara, Graziana Assalve, Alessandra Ferramosca · 2023 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Focused Screening Identifies Different Sensitivities of Human TET Oxygenases to the Oncometabolite 2-Hydroxyglutarate
Roman Belle, Hilal Saraç, E. Salah, Bhaskar Bhushan, Aleksandra Szykowska, Grace Roper, Anthony Tumber, Skirmantas Kriaučionis, N. Burgess-Brown, Christopher John Schofield et al. · 2024 · Journal of Medicinal Chemistry
The potential of 2-oxoglutarate oxygenases acting on nucleic acids as therapeutic targets
Armin Thalhammer, Wei Shen Aik, Eleanor A. L. Bagg, Christopher John Schofield · 2012 · Drug Discovery Today Therapeutic Strategies
Higher-Level Pathway Objectives of Epigenetic Therapy: A Solution to the p53 Problem in Cancer
Vamsidhar Velcheti, Tomas Radivoyevitch, Yogen Saunthararajah · 2017 · American Society of Clinical Oncology Educational Book
Renal oncometabolite L-2-hydroxyglutarate imposes a block in kidney tubulogenesis: Evidence for an epigenetic basis for the L-2HG-induced impairment of differentiation
Mary L. Taub, Nader H. Mahmoudzadeh, Jason M. Tennessen, Sunil Sudarshan · 2022 · Frontiers in Endocrinology
Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Jennie Webster Taylor, Andrew S Chi, Daniel P. Cahill · 2013 · PubMed
Epigenetics and blood disorders
Bastian Scholz, Rolf Marschalek · 2012 · British Journal of Haematology
Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy
Luyuan Li, Josiane E. Eid, Ana Cristina Paz, Jonathan C. Trent · 2017 · BioDrugs